Carcinoid Syndrome Management Market Research Report- Global Forecast To 2027

Global Carcinoid Syndrome Management Market Information, by organs affected (Small Intestine, Lungs, Rectum, Appendix, Colon, Stomach, Pancreas, Liver and others) by Treatment (Chemotherapy, Biological therapy, and Hepatic Artery Embolization Agents), by End users (Hospital, Clinics, Cancer institute and treatment centers) Forecast to 2027

ID: MRFR/MED/2100-HCR | February 2021 | Region: Global | 85 pages


Market Synopsis of Global Carcinoid Syndrome Management:


Market Scenario:


Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.


Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.


Study objectives:



  • To provide detail analysis of parent market and the changing market dynamics of the industry.

  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the global carcinoid syndrome management market.

  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future growth prospect.

  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the market.

  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the global  Carcinoid Syndrome Management.


Figure 1           Global Carcinoid Syndrome Management Market by Organs Affected
Carcinoid Syndrome Management Market


Key players of Global Carcinoid Syndrome Management Market:


Key players profiled in the report are Novartis International AG (Sandoz) (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (USA), Ipsen Biopharmaceuticals, Inc.(US), Sirtex Medical Limited (Australia) , BTG International Ltd. (UK), Wockhardt Ltd. , and  Sun Pharmaceutical Industries Limited (India),


Segments:


The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
The report for global Carcinoid Syndrome Management by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Intended Audience



  • Global carcinoid syndrome management or treatment device manufacturers & suppliers

  • Contract research organizations (CROs)

  • Research and development (R&D) companies

  • Government research laboratories

  • Independent research laboratories

  • Government and independent regulatory authorities

  • Market research and consulting service providers

  • Academic institutes and universities


 



Frequently Asked Questions (FAQ) :


Rise in smoking among the populace, rising cases of hormonal disorders, and high levels of carcinogens among the people in developed countries are major factors driving the global carcinoid syndrome management market.

Low availability of drugs to manage the disease is the major restraining factor of the global carcinoid syndrome management market.

The Americas can dominate in the global carcinoid syndrome management market till 2023.

Pharmascience Inc., Novartis International AG, Mylan N.V., Ipsen Biopharmaceuticals, Inc., Wockhardt Ltd., Teva Pharmaceutical Industries Ltd., BTG International Ltd., Sun Pharmaceutical Industries Limited, Sirtex Medical Limited, and Omega Laboratories Ltd. are major players of the global carcinoid management market.

Acquisitions seem to be the major strategy of players in the global carcinoid syndrome management market.

Table of Contents

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED

5.1 SMALL INTESTINE

5.2 RECTUM

5.3 LUNGS

5.4 APPENDIX

5.5 COLON

5.6 STOMACH

5.7 PANCREAS

5.8 LIVER

5.9 OTHERS

6. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE

6.1 CHEMOTHERAPY

6.3 BIOLOGICAL THERAPY

6.4 HEPATIC ARTERY EMBOLIZATION AGENT

7. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS

7.1 HOSPITALS

7.2 CLINICS

7.3 CENCER INSTITUTIONS AND TREATMENT CENTERS

7.4 OTHERS

8. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION

8.1 NORTH AMERICA

8.1.1 INTRODUCTION

8.2 EUROPE

82.1 INTRODUCTION

8.3 ASIA-PACIFIC

8.3.1 INTRODUCTION

8.4 MIDDLE EAST & AFRICA

8.4.1 INTRODUCTION

9. COMPETITIVE LANDSCAPE

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9..1.1 STRATEGIC PARTNERSHIP

10..1.2 MERGER & ACQUISITION

10 COMPANY PROFILE

10.1 BTG INTERNATIONAL LTD.

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 IPSEN BIOPHARMACEUTICALS, INC.,

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 NOVARTIS INTERNATIONAL AG (SANDOZ)

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 STRATEGY

10.3.5 KEY DEVELOPMENT

10.4 PHARMASCIENCE INC.,

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 OTHERS

List of Tables

TABLE 1 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKETBY END USERS 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED

FIGURE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE

FIGURE 5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS

FIGURE 6 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION

FIGURE 7 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)